Abstract
PURPOSE: This research evaluates the efficacy of integrating immunotherapy with surgical resection in the treatment of "oral squamous cell carcinoma (OSCC)." By analyzing clinical outcomes, we aim to provide evidence for a combined therapeutic approach. METHODS: A cohort of 120 OSCC patients was divided into two groups: surgical resection alone (n = 60) and surgical resection with adjunctive immunotherapy (n = 60). Treatment outcomes were assessed using survival rates, recurrence rates, and quality-of-life indicators. RESULTS: Patients in the combined therapy group showed significantly improved three-year overall survival (78% vs. 62%) and reduced recurrence rates (15% vs. 28%). Quality-of-life scores were also higher in the immunotherapy group. CONCLUSION: Integrating immunotherapy with surgical resection improves clinical outcomes in OSCC, suggesting a promising direction for multimodal treatment strategies.